Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Drug developer Redx Pharma receives huge vote of confidence in the form of US$1mln grant to develop its next-generation antibiotic

The money from CARB-X will enable Redx to move its Gram-negative antibacterial programme into the next stage of development
Drug developer Redx Pharma receives huge vote of confidence in the form of US$1mln grant to develop its next-generation antibiotic
Pictured Gram-negative bacteria

Drug developer Redx Pharma (LON:REDX) has been awarded a US$1mln grant by a US-UK partnership set up to accelerate the development of new antibiotics that combat drug resistant Gram-negative bacteria.

The money from CARB-X will enable Redx to move its Gram-negative antibacterial programme into the next stage of development with a prospective partner.

WATCH: Grant "testament to great science", saw RedX CSO ...

Chief executive Dr Neil Murray said: “We are delighted to be collaborating with CARB-X, a truly innovative initiative that is targeting the development of new life-saving antibacterials and diagnostics.

“Receiving this grant today is testament to the great science that exists at Redx.

“This grant cements a path forward for our recently announced strategy, to secure external partners to ensure that our high quality anti-infective science will continue whilst we sharpen our focus on the clinical development of our oncology and immunology programmes.”

Redx was one of just 11 companies to receive financial backing from CARB-X, one of the world’s largest public-private partnerships.

The money will be staggered over 18 months with an option for future tiered milestone payments “to drive scientific progress against globally challenging drug resistant Gram-negative bacteria”, the company said.

CARB-X was launched by the US Department of Health and Human Services and is funded by the Biomedical Advanced Research and Development Authority and the Wellcome Trust, a UK charity.

Ian_55ae0ddd437b7.jpg
Why Invest In Redx Pharma Plc? Read More Here

Register here to be notified of future REDX Company articles
View full REDX profile

Redx Pharma Plc Timeline

Related Articles

a child with asthma using an inhaler
September 22 2016
Phase II results for its prospective asthma treatment are due next year, while its LOXL2 collaboration with Pharmaxis is set for a Phase I trial in 2017
genomics.jpg
October 04 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.
Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use